First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the pa

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's p

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranost

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent b

Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor up

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual

Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase

Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase

Radiopharm Theranostics (NASDAQ: RADX) executives and clinical investigators highlighted new interim

RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and

Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX -

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been

Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been

SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiophar

Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session vol

92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI im